P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
Main Authors: | L. Bischof, J. Ussmann, D. Brauer, D. Backhaus, L. Herrmann, G.-N. Franke, V. Vucinic, K. H. Metzeler, U. Platzbecker, S. Schwind, M. Jentzsch |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844924.32286.18 |
Similar Items
-
P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
by: M. Jentzsch, et al.
Published: (2022-06-01) -
PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
by: Jule Ussmann, et al.
Published: (2023-08-01) -
P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH
by: M. Jentzsch, et al.
Published: (2022-06-01) -
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
by: Madlen Jentzsch, et al.
Published: (2022-12-01) -
P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
by: Madlen Jentzsch, et al.
Published: (2023-08-01)